Global AI In Vitro Diagnostic 麻豆原创 Growth (Status and Outlook) 2025-2031

Publication ID:

LPI06250126

Publication Date:

June 17, 2025

Pages:

138

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

IT Services [2]

Software [3]

Computing & Electronics [4]

Description:

The global AI In Vitro Diagnostic market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
The global market for in vitro diagnostics (IVD) was growing steadily and was expected to continue its growth in the coming years.
麻豆原创 Overview: The in vitro diagnostics market involves medical devices, instruments, and reagents used for diagnostic testing of samples such as blood, urine, tissue, and other bodily fluids. AI in vitro diagnostics refers to the integration of artificial intelligence and machine learning technologies into these diagnostic tools and processes.
Growth Drivers: The market for AI in vitro diagnostics has been driven by factors such as increasing demand for personalized medicine, rising prevalence of chronic and infectious diseases, technological advancements in diagnostics, and the need for efficient and accurate diagnostic solutions.
Application Areas: AI has found applications in various areas of in vitro diagnostics, including clinical chemistry, immunoassays, microbiology, hematology, genetic testing, and molecular diagnostics. AI algorithms can aid in data analysis, interpretation, and decision-making, improving the accuracy and efficiency of diagnostic procedures.
The 鈥淎I In Vitro Diagnostic Industry Forecast鈥� looks at past sales and reviews total world AI In Vitro Diagnostic sales in 2024, providing a comprehensive analysis by region and market sector of projected AI In Vitro Diagnostic sales for 2025 through 2031. With AI In Vitro Diagnostic sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world AI In Vitro Diagnostic industry.
This Insight Report provides a comprehensive analysis of the global AI In Vitro Diagnostic landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on AI In Vitro Diagnostic portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global AI In Vitro Diagnostic market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for AI In Vitro Diagnostic and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global AI In Vitro Diagnostic.
This report presents a comprehensive overview, market shares, and growth opportunities of AI In Vitro Diagnostic market by product type, application, key players and key regions and countries.
Segmentation by Type:
Next-Generation Sequencing Technology
PCR Technology
Chemistry and IA Technology
Pathology Technology
Segmentation by Application:
Cancer Diagnostics
Infectious Disease Testing
Metabolic Testing
Cardiac Testing
Diabetes Testing
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Renalytix
Seegene
Sysmex
PathAI
Prognos
Qiagen
CloudMedX Health
Deepcell
Digital Diagnostics
EKF Diagnostics Holdings
Freenome
GE Healthcare
Glooko
Adaptive Biotechnologies
Aidoc
Anumana
ARUP Laboratories
K Health
Lunit

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global AI In Vitro Diagnostic 麻豆原创 Size (2020-2031)
2.1.2 AI In Vitro Diagnostic 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for AI In Vitro Diagnostic by Country/Region (2020, 2024 & 2031)
2.2 AI In Vitro Diagnostic Segment by Type
2.2.1 Next-Generation Sequencing Technology
2.2.2 PCR Technology
2.2.3 Chemistry and IA Technology
2.2.4 Pathology Technology
2.3 AI In Vitro Diagnostic 麻豆原创 Size by Type
2.3.1 AI In Vitro Diagnostic 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global AI In Vitro Diagnostic 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 AI In Vitro Diagnostic Segment by Application
2.4.1 Cancer Diagnostics
2.4.2 Infectious Disease Testing
2.4.3 Metabolic Testing
2.4.4 Cardiac Testing
2.4.5 Diabetes Testing
2.5 AI In Vitro Diagnostic 麻豆原创 Size by Application
2.5.1 AI In Vitro Diagnostic 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global AI In Vitro Diagnostic 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 AI In Vitro Diagnostic 麻豆原创 Size by Player
3.1 AI In Vitro Diagnostic 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global AI In Vitro Diagnostic Revenue by Player (2020-2025)
3.1.2 Global AI In Vitro Diagnostic Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global AI In Vitro Diagnostic Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 AI In Vitro Diagnostic by Region
4.1 AI In Vitro Diagnostic 麻豆原创 Size by Region (2020-2025)
4.2 Global AI In Vitro Diagnostic Annual Revenue by Country/Region (2020-2025)
4.3 Americas AI In Vitro Diagnostic 麻豆原创 Size Growth (2020-2025)
4.4 APAC AI In Vitro Diagnostic 麻豆原创 Size Growth (2020-2025)
4.5 Europe AI In Vitro Diagnostic 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa AI In Vitro Diagnostic 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas AI In Vitro Diagnostic 麻豆原创 Size by Country (2020-2025)
5.2 Americas AI In Vitro Diagnostic 麻豆原创 Size by Type (2020-2025)
5.3 Americas AI In Vitro Diagnostic 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC AI In Vitro Diagnostic 麻豆原创 Size by Region (2020-2025)
6.2 APAC AI In Vitro Diagnostic 麻豆原创 Size by Type (2020-2025)
6.3 APAC AI In Vitro Diagnostic 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe AI In Vitro Diagnostic 麻豆原创 Size by Country (2020-2025)
7.2 Europe AI In Vitro Diagnostic 麻豆原创 Size by Type (2020-2025)
7.3 Europe AI In Vitro Diagnostic 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa AI In Vitro Diagnostic by Region (2020-2025)
8.2 Middle East & Africa AI In Vitro Diagnostic 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa AI In Vitro Diagnostic 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global AI In Vitro Diagnostic 麻豆原创 Forecast
10.1 Global AI In Vitro Diagnostic Forecast by Region (2026-2031)
10.1.1 Global AI In Vitro Diagnostic Forecast by Region (2026-2031)
10.1.2 Americas AI In Vitro Diagnostic Forecast
10.1.3 APAC AI In Vitro Diagnostic Forecast
10.1.4 Europe AI In Vitro Diagnostic Forecast
10.1.5 Middle East & Africa AI In Vitro Diagnostic Forecast
10.2 Americas AI In Vitro Diagnostic Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 AI In Vitro Diagnostic Forecast
10.2.2 Canada 麻豆原创 AI In Vitro Diagnostic Forecast
10.2.3 Mexico 麻豆原创 AI In Vitro Diagnostic Forecast
10.2.4 Brazil 麻豆原创 AI In Vitro Diagnostic Forecast
10.3 APAC AI In Vitro Diagnostic Forecast by Region (2026-2031)
10.3.1 China AI In Vitro Diagnostic 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 AI In Vitro Diagnostic Forecast
10.3.3 Korea 麻豆原创 AI In Vitro Diagnostic Forecast
10.3.4 Southeast Asia 麻豆原创 AI In Vitro Diagnostic Forecast
10.3.5 India 麻豆原创 AI In Vitro Diagnostic Forecast
10.3.6 Australia 麻豆原创 AI In Vitro Diagnostic Forecast
10.4 Europe AI In Vitro Diagnostic Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 AI In Vitro Diagnostic Forecast
10.4.2 France 麻豆原创 AI In Vitro Diagnostic Forecast
10.4.3 UK 麻豆原创 AI In Vitro Diagnostic Forecast
10.4.4 Italy 麻豆原创 AI In Vitro Diagnostic Forecast
10.4.5 Russia 麻豆原创 AI In Vitro Diagnostic Forecast
10.5 Middle East & Africa AI In Vitro Diagnostic Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 AI In Vitro Diagnostic Forecast
10.5.2 South Africa 麻豆原创 AI In Vitro Diagnostic Forecast
10.5.3 Israel 麻豆原创 AI In Vitro Diagnostic Forecast
10.5.4 Turkey 麻豆原创 AI In Vitro Diagnostic Forecast
10.6 Global AI In Vitro Diagnostic Forecast by Type (2026-2031)
10.7 Global AI In Vitro Diagnostic Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 AI In Vitro Diagnostic Forecast
11 Key Players Analysis
11.1 Renalytix
11.1.1 Renalytix Company Information
11.1.2 Renalytix AI In Vitro Diagnostic Product Offered
11.1.3 Renalytix AI In Vitro Diagnostic Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 Renalytix Main Business Overview
11.1.5 Renalytix Latest Developments
11.2 Seegene
11.2.1 Seegene Company Information
11.2.2 Seegene AI In Vitro Diagnostic Product Offered
11.2.3 Seegene AI In Vitro Diagnostic Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 Seegene Main Business Overview
11.2.5 Seegene Latest Developments
11.3 Sysmex
11.3.1 Sysmex Company Information
11.3.2 Sysmex AI In Vitro Diagnostic Product Offered
11.3.3 Sysmex AI In Vitro Diagnostic Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 Sysmex Main Business Overview
11.3.5 Sysmex Latest Developments
11.4 PathAI
11.4.1 PathAI Company Information
11.4.2 PathAI AI In Vitro Diagnostic Product Offered
11.4.3 PathAI AI In Vitro Diagnostic Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 PathAI Main Business Overview
11.4.5 PathAI Latest Developments
11.5 Prognos
11.5.1 Prognos Company Information
11.5.2 Prognos AI In Vitro Diagnostic Product Offered
11.5.3 Prognos AI In Vitro Diagnostic Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 Prognos Main Business Overview
11.5.5 Prognos Latest Developments
11.6 Qiagen
11.6.1 Qiagen Company Information
11.6.2 Qiagen AI In Vitro Diagnostic Product Offered
11.6.3 Qiagen AI In Vitro Diagnostic Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 Qiagen Main Business Overview
11.6.5 Qiagen Latest Developments
11.7 CloudMedX Health
11.7.1 CloudMedX Health Company Information
11.7.2 CloudMedX Health AI In Vitro Diagnostic Product Offered
11.7.3 CloudMedX Health AI In Vitro Diagnostic Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.7.4 CloudMedX Health Main Business Overview
11.7.5 CloudMedX Health Latest Developments
11.8 Deepcell
11.8.1 Deepcell Company Information
11.8.2 Deepcell AI In Vitro Diagnostic Product Offered
11.8.3 Deepcell AI In Vitro Diagnostic Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.8.4 Deepcell Main Business Overview
11.8.5 Deepcell Latest Developments
11.9 Digital Diagnostics
11.9.1 Digital Diagnostics Company Information
11.9.2 Digital Diagnostics AI In Vitro Diagnostic Product Offered
11.9.3 Digital Diagnostics AI In Vitro Diagnostic Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.9.4 Digital Diagnostics Main Business Overview
11.9.5 Digital Diagnostics Latest Developments
11.10 EKF Diagnostics Holdings
11.10.1 EKF Diagnostics Holdings Company Information
11.10.2 EKF Diagnostics Holdings AI In Vitro Diagnostic Product Offered
11.10.3 EKF Diagnostics Holdings AI In Vitro Diagnostic Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.10.4 EKF Diagnostics Holdings Main Business Overview
11.10.5 EKF Diagnostics Holdings Latest Developments
11.11 Freenome
11.11.1 Freenome Company Information
11.11.2 Freenome AI In Vitro Diagnostic Product Offered
11.11.3 Freenome AI In Vitro Diagnostic Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.11.4 Freenome Main Business Overview
11.11.5 Freenome Latest Developments
11.12 GE Healthcare
11.12.1 GE Healthcare Company Information
11.12.2 GE Healthcare AI In Vitro Diagnostic Product Offered
11.12.3 GE Healthcare AI In Vitro Diagnostic Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.12.4 GE Healthcare Main Business Overview
11.12.5 GE Healthcare Latest Developments
11.13 Glooko
11.13.1 Glooko Company Information
11.13.2 Glooko AI In Vitro Diagnostic Product Offered
11.13.3 Glooko AI In Vitro Diagnostic Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.13.4 Glooko Main Business Overview
11.13.5 Glooko Latest Developments
11.14 Adaptive Biotechnologies
11.14.1 Adaptive Biotechnologies Company Information
11.14.2 Adaptive Biotechnologies AI In Vitro Diagnostic Product Offered
11.14.3 Adaptive Biotechnologies AI In Vitro Diagnostic Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.14.4 Adaptive Biotechnologies Main Business Overview
11.14.5 Adaptive Biotechnologies Latest Developments
11.15 Aidoc
11.15.1 Aidoc Company Information
11.15.2 Aidoc AI In Vitro Diagnostic Product Offered
11.15.3 Aidoc AI In Vitro Diagnostic Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.15.4 Aidoc Main Business Overview
11.15.5 Aidoc Latest Developments
11.16 Anumana
11.16.1 Anumana Company Information
11.16.2 Anumana AI In Vitro Diagnostic Product Offered
11.16.3 Anumana AI In Vitro Diagnostic Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.16.4 Anumana Main Business Overview
11.16.5 Anumana Latest Developments
11.17 ARUP Laboratories
11.17.1 ARUP Laboratories Company Information
11.17.2 ARUP Laboratories AI In Vitro Diagnostic Product Offered
11.17.3 ARUP Laboratories AI In Vitro Diagnostic Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.17.4 ARUP Laboratories Main Business Overview
11.17.5 ARUP Laboratories Latest Developments
11.18 K Health
11.18.1 K Health Company Information
11.18.2 K Health AI In Vitro Diagnostic Product Offered
11.18.3 K Health AI In Vitro Diagnostic Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.18.4 K Health Main Business Overview
11.18.5 K Health Latest Developments
11.19 Lunit
11.19.1 Lunit Company Information
11.19.2 Lunit AI In Vitro Diagnostic Product Offered
11.19.3 Lunit AI In Vitro Diagnostic Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.19.4 Lunit Main Business Overview
11.19.5 Lunit Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.